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Arylated 5-hydroxy–pyrrol-2-ones were prepared in 2 synthetic 
steps from muco- chloric acid and optimised as CCK2 selective 
ligands using radiolabelled binding assays. CCK antagonism was 
confirmed for the ligands in isolated tissue preparations. DSS 
(dextran sulfate sodium) induced inflammation was analysed for 
derivative 7 and PNB-001 with L-365,260 as standard. The IC50 of 
PNB-001 was determined as 10 nM. Subsequent in vivo evaluation 
confirmed anti-inflammatory activity with respect to IBD assays. 
The best molecule, PNB-001, showed analgesic activity in the 
formalin test and in the hotplate assay the analgesic effect of 1.5 
mg/kg PNB-001 was equivalent to 40 mg/kg tramadol. The CCK2 
selective antagonist PNB-001 protected rats against indomethacin 
induced ulceration at similar doses. The GI protection activity was 
found more potent than the 10 mg/kg dose of prednisolone, 
which served as standard. 
Introduction 
Inflammatory bowel syndrome (IBS) is a complex symptom of 
unknown ethology, characterized by abdominal pain or discomfort 
associated with disturbed defecation and often bloating. 
Inflammatory bowel disease (IBD) encompasses at least two forms 
of intestinal inflammation being expressed as ulcerative colitis and 
Crohn's disease. Although many other inflammatory disorders 
affect the gastrointestinal tract, most can be distinguished by a 
specific underlying process from IBD. Stress may exacerbate IBS 
symptoms and the CCK2 receptor is known to mediate anxiety
1
 and 
panic attacks. Though several drugs such as anti-cholinergic-, anti-
spasmodic- agents and tricyclic anti-depressants are of limited use 
for IBS and steroids for IBD, inflammatory bowel disease is still 
classified as unmet medical need and hundreds of studies are 
ongoing worldwide.  
Aim of the drug discovery programme was to target the underlying 
mechanism of the disease, thus targeting Cholecystokinin (CCK) 
pathways. CCK, a peptide hormone, which is extensively found in 
the gastrointestinal tract (GIT) is widely distributed through the 
nervous system
2
. Cholecystokinin acts as a neuromodulator / gut 
hormone and CCK-ligands, agonists as well as antagonists
3
, have 
been extensively investigated as potential drug targets
4
. CCK-
antagonists were studied as growth inhibitors in certain forms of 
cancer
5
, as anxiolytics
6
, in the treatment of schizophrenia
7
, satiety
8
 
and as anti-panic agents
9
. An agonist, the shortened CCK 
tetrapeptide, was found to induce panic in patients
10
.  
Despite the progress of several CCK receptor antagonists
11
 to 
different phases of clinical trials, only proglumide was marketed as 
Milid for the treatment of gastric ulcer. 
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Figure 1. CCK2 / gastrin antagonists, Merck standard and most 
recent addition. 
 
Merck’s standard CCK2 antagonist
12
 is outlined in Figure 1. Z-360 is 
the most recent derivative derived from this original lead structure, 
in which the N was moved to the 5-position. The N-1 was alkylated, 
the 5 phenyl group was replaced by a cyclohexyl group and the 
water solubility was enhanced by converting the Me group on the 
side chain into a carboxylic acid. All structural optimisations did not 
address the main underlying problem with respect to poor 
pharmacokinetic properties, such as a low solubility and very low 
membrane penetration resulting from the large polar surface area 
of the molecule. 
PNB Vesper Life Science systematically investigated the hydroxyl-
pyrrolone scaffold and the isobutyl derivative
13
 served as lead 
structure on this programme towards novel anti-inflammatory 
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analgesics targeting the underlying mechanism of inflammatory 
ulceration.   
A full biological evaluation of lactame 14, now PNB-001, will be 
reported here, in this publication from a CCK-5 pentagastrin 
antagonism to initial anti-inflammatory analgesic activity. 
 
Results and discussions 
Synthesis  
Mucochloric acid was reacted in presence of a Lewis acid via SE 
reactions into a series of arylated dichlorinated furanones. In 
addition to halogenated X=Cl, F 5-arylated 2(5H)-furanones 
containing further donor substituents were prepared. The chemical 
yields were generally lower and binding affinity was also decreased 
in the resulting final molecules. Arylated 2(5H)-furanones, 
containing nitro- groups or trifluoro-methyl groups could not be 
prepared. 
Subsequent reaction of the 5-arylated 3,4-dichloro-2(5H)-furanones 
with amines, in particular with aryl alkyl amines, furnished 15 
arylated N-alkylated hydroxyl-pyrrolones and the 2
nd
 step of the 
synthetic sequence is outlined in Scheme 1. 
 
 
 
 
Scheme 1. Synthesis of lactames 1-15 from 3,4-dichloro- 5-arylated 
2(5H) furanones. For the synthesis of building blocks from 
mucochloric acid see Lattmann et al, MedChemComm 2016. 
 
 
The 5-arylated 2(5H)-furanones reacted selectively in the ester 
position and no reaction in the 4-position was observed.  Previously 
the substitution  in the 4-position was described for pseudo- 
esters
14
, and here a ring -opening ring -closure mechanism for the 
formation of hydroxyl-pyrrolones is proposed in scheme 2. 
The first step in the reaction sequence of the dichlorinated 2(5H)-
furanone is the ring opening and amide formation from the 
corresponding lactone. The keto form of the acyclic amide was then 
in situ converted into a lactame under the elimination of hydrogen 
chloride.   
 
Analysis by chiral HPLC showed a 50:50 racemic mixture of the 
novel template in solution in methanol. 
 
 
 
Scheme 2. Chemical mechanism for the formation of 5-hydroxy-5-
aryl-pyrrol-2-ones with amines. 
 
SAR optimisation 
Initially SAR were fully explored and optimised for the CCK2/gastrin 
receptor, using a radiolabelled binding assay with iodinated CCK8. 
The results, expressed in IC50, are outlined in table 1. 
Lorglumide served as CCK1 standard and L-365,260 was used as 
CCK2 standard. For a better comparison the initial starting point, the 
CCK1 antagonist PNB-028, is also included in Table 1. 
Cyclic substituents on the N-position, such as cyclopropyl-, 
cyclopentyl- and cyclohexyl provided activity in the micromolar 
range (Lactame 1-5). Anilines were inactive and the introduction of 
the benzyl group furnished a dual ligand in nanomolar range 
(lactame 7). Halogen atoms on the 5 phenyl group marginally 
enhanced the binding affinity and the best derivative was the 
fluorinated N-benzyl lactame 9. 
Donor substituents on the 5-phenyl group, such as para-methoxy 
and methyl groups resulted in ligands with manifold lower activity 
(lactame 10, 11). The introduction of a chiral amine, such as methyl 
benzyl amine provided diastereoisomers (12, 13), which were 
separated by column chromatography, but both isomers occurred a 
lower affinity than the parent benzyl derivative 7. Further 
optimisation on the N-benzyl group was performed, but the 
introduction of a para F- and methoxy- group, using p-fluorobenzyl 
amine and p-methoxy benzylamine, did not enhance the binding 
affinity for the CCK receptor. 
The introduction of a spacer, a single CH2 group, resulted in a 
phenyl-ethyl derivative 14, which represented a highly CCK2 
selective ligand.  
Lactame 14 is 450 times selective for the CCK2 / gastrin receptor. 
Halogenation, the introduction of a para- chlorine atom on the 
phenyl–position, lactame 15, did not enhance binding affinity any 
further; possibly due to drug receptor interaction of the phenyl 
group with a lipophilic cavity within the CCK receptor.  
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Table 1. CCK binding affinity using radioligands with cortex and 
pancreatic membranes. IC50 is presented in micromolar; N=3. 
 
Lactame  X= R= CCK-A 
[µM] 
CCK-B 
[µM] 
Lorglumide - - 0.17±0.01 >10 
L-356,260 - - 0.25±0.01 0.003±0.001 
PNB-028 F Isobutyl- 0.012±0.001 0.75±0.21 
1 H Cyclopropyl- 7.5±0.3 >10 
2 Cl Cyclopropyl- 4.0±0.3 >10 
3 H Cyclopentyl- 0.36±0.30 0.84±0.40 
4 Cl Cyclopentyl- 2.50±0.20 >10 
5 H Cyclohexyl- >10 >10 
6 H Ph- >10 >10 
7 H Bz- 0.80±0.04 0.022±0.002 
8 Cl Bz- 0.51±0.04 0.020±0.004 
9 F Bz- 0.32±0.01 0.017±0.002 
10 MeO Bz- 0.21±0.02 4.5±0.4 
11 Me Bz- 1.5±0.04 4.1±0.3 
12 H  Methylbenzyl- 0.60±0.04 0.21±0.01 
13 H Methylbenzyl- 0.42±0.03 0.21±0.15 
14 H Phenylethyl- >10 0.022±0.002 
15 Cl Phenylethyl- >10 0.030±0.001 
 
Molecular modelling - Ligand docking 
The docking of the phenylethyl pyrrolone 14 into the CCK2 receptor 
is outlined in figure 2 for one final pose of minimal energy and some 
key drug receptor interactions are highlighted.  
The 2-carbonyl group of the central pyrrolone template interacts via 
hydrogen binding with the N group of Trp-114. The phenyl group of 
the N-phenylethyl- side chain binds towards the aromatic indole 
system of Trp-114 and electron withdrawing groups should enhance 
these aromatic interactions. The lipophilic pocket in the CCK2 
receptor comprising of Ile-184 and Leu-133, allows principally a 
wide range of substituents, but only phenyl and not cyclo-hexyl can 
be realised synthetically. The 5-phenyl group of the pyrrolone 
template binds via Ile-184 and Leu-133, based on van der Waals 
interactions and not aromatic interactions. Therefore, the 
introduction of electron withdrawing groups on the 5- phenyl 
group, such as a chlorine atom, do not enhance binding affinity and 
optimisation on this side is overall with limited effect. Interestingly, 
the metabolism of the 5-phenyl derivative 14, may result in a p-
hydroxy-phenyl metabolite, which may interact additionally with 
His-122 via a strong hydrogen bond and the role of metabolites is 
currently under investigation. 
 
 
 
Figure 2. Docking of CCK antagonist PNB-001 into the CCK2 
receptor. 
 
The molecular structure of lactame 14, (Table 1) which is now PNB-
001 was designed from an iso-propyl lead structure via the benzyl 
derivative 7 (Figure 3). PNB-001 contains the N-phenyl-ethyl 
substituent, which is required for high CCK2 / gastrin selectivity
15
. 
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Figure 3. Lead design. From a CCK1 antagonist to a CCK2 selective 
molecule.  
The mixed dual acting N- benzylated pyrrolone 7 (Table 1) is 
showing the expected pharmacological profile of a mixed CCK 
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COMMUNICATION Journal Name 
antagonist
16
 and its role in brain cancer is currently being 
elucidated.  
The phenyl ethyl derivative PNB-001 completed preclinical 
development as anti-inflammatory analgesic and progressed into 
Phase 1 clinical trials for the treatment of IBD. 
 
Isolated tissue preparations 
CCK antagonism 
The CCK2 selective ligand PNB-001, occurred a potent binding 
affinity and the CCK-antagonism was studied
17
 using pentagastrin, 
CCK-5 induced contractions of the rat duodenum. 
Initially CCK4 was used
18
, but CCK4 has a low solubility and low 
potency in the micro-molar range.  The best CCK2 selective agonist 
is CCK-5 and this was used to analyse the agonist or antagonist 
properties of the ligand.   
 
Figure 4. Responses to CCK-5 in the absence and presence of PNB-
001; CCK-5, CCK-5 +10 nM PNB-001, CCK-5 +30 nM PNB-001, CCK-5 + 
100 nM PNB-001; N = 2 for each data point. Values are ±SEM. 
The concentration response curve of pentagastrin, CCK-5, was 
recorded and shifted to the right by a nanomolar concentration of 
PNB-001, thus confirming the antagonistic properties
19
 of this 
ligand. 
100 nM of PNB-001 with 30 min of incubation time fully blocked the 
CCK4 and CCK5 induced contractions. For the 5 min incubation cycle, 
10 nM of PNB-001 shifted the CCK-5 concentration response curve 
to the right and from 30 nM onwards, the antagonist PNB-001 
showed a reduced maximum response. At high nano molar 
concentrations PNB-001 acted as unsurmountable 
gastrin/cholecystokinin antagonist.  
As the clinical trial outcome of selective CCK/gastrin antagonists 
was found questionable in the treatment of anxiety and 
depression
20
, the aim of the programme was, to focus on selectively 
designing CCK2 antagonists for the gastrointestinal system and to 
focus on inflammation thereof. 
Inflammatory bowel disease, IBD, is classified an unmet medicinal 
need by the FDA and allows fast track approval. The indomethacin 
induced ulceration is a standard in vivo assay for IBD
21
.  
In vitro inflammation 
In vitro, spontaneous contractions correlate with inflammation and 
anti-inflammatory steroids such as dexamethasone reduced 
spontaneous contractions of the duodenum
22
. 
DSS, dextran sulfonic acid sodium, is a standard agent to induce 
inflammation for IBD in vivo and in vitro the effect is slower and 
milder than for Trinitro-benzene sulfonic acid, TNBSA
23
.  
DSS was used here in vitro using isolated organ preparations and 
preparations of the duodenum worked best in this assay
24
.  
L-365,260 was applied as CCK2 standard and the mixed CCK 
antagonist HPhBz, lactame 7, together with the highly CCK2 
selective antagonist PNB-001 were all tested under the same 
conditions. The concentration response curves, showing how these 
agents inhibit contractions a very low concentrations, are outlined 
in Figure 5. 
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Figure 5.The inhibitory concentration-response curves of PNB-001, 
L-365,260 and HPhBz (lactame 7) for DSS stimulated contractions. 
An IC50 of 1 nM was determined for CCK2 antagonist PNB-001. The 
Merck CCK2 standard occurred a ten times lower IC50 and the 
benzylated derivative HPhBz, lactame 7, had the lowest anti-
inflammatory effect. Considering the chemical similarity between 
the lactame 7 and PNB-001, the addition of an extra CH2 group 
resulted in a remarkable effect. The CCK1 antagonism may oppose 
the anti-inflammatory effect, but the possible mechanistic pathway 
is outside the scope of this publication. 
Based on the in vitro results with respect to anti-inflammatory 
activity, PNB-001 was selected for further in vivo assays. This 
programme was concerned with inflammation of the GI tract and 
the indomethacin induced ulceration is the best model for IBD, 
inflammatory bowel disease and ulcerative colitis, which is 
associated with the release of gastric acid. Here, the anti-
inflammatory action of the molecule, supported by anti-gastric 
activity, was supposed to create a synergistic therapeutic effect. 
 
Page 4 of 7
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Please do not adjust margins 
In vivo evaluation  
Inflammatory/ulceration protection 
Gastrin triggers the release of gastric acid in the stomach and the 
content of the GI system moves from the duodenum, jejunum via 
ileum to the colon. The inflammation was assessed in this order by 
organ weight and inflammation scores. The measurement of weight 
as inflammation parameter is reliable and the induction of 
inflammation / ulceration resulted in an increased organ weight. 
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Figure 6. Indomethacin induced ulceration. Weights of the GI tract 
treated by PNB-001. 
Indomethacin increased weight in all observed organ parts and this 
increase of weight was reduced dose dependently by PNB-001 for 
the duodenum, jejunum, and ileum. The effect of protection is 
observed for all parts of the GI system and PNB-001 performed 
better than the steroid standard prednisolone. 
The second accessed parameter was scores of inflammation and 
the results are outlined in Figure 7. 
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Figure 7. Inflammation score of the GI tract treated by PNB-001. 
Treatment is presented for each individual organ and scores of 
inflammation were determined. Most interestingly the gaps in the 
treatment groups with zero inflammation are present in the 
duodenum for both the 5 and the 20 mg /kg dose of PNB-001 via 
oral administration. Indomethacin induced an inflammation score 
of 5 in the duodenum, which was fully protected by both doses of 
the CCK B antagonist and reduced to 2 by prednisolone at 10 mg/kg. 
In figure 8 selected photos of the gastrointestinal system with 
ulceration are depicted. In the duodenum the perforation is clearly 
visible and this is fully prevented by a low 5 mg /kg dose of PNB-
001. A similar effect is seen for the jejunum on indomethacin 
induced ulcers and this damage of the GI system was prevented by 
PNB-001. 
 
 
 
Figure 8. Top: Photos of duodenum; below jejunum. Selected parts 
of the GI system, indomethacin induced ulcers and prevented by 
CCK2 / gastrin antagonist PNB-001. 
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 Analgesic evaluation 
CCK antagonists potentiate the analgesia of opiates and usually, 
except for proglumide, have no analgesic effect on their own 
25
. For 
Z-360 an interesting weak analgesic effect in the formalin test was 
observed
26
.  
Thus, a first evaluation of the analgesic properties of PNB-001 was 
performed using the formalin test. 
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Figure 9. Analgesic anti-inflammatory activity of PNB-001 on 
formalin induced pain in rats. 
 
Opiates, such as morphine, reduce the response in form of licks and 
bites to formalin in the first phase of the assay. Anti-inflammatory 
agents are active in this assay in the second phase.  
PNB-001 showed only at the 1.5 mg/kg dose some opiate like 
effects (phase 1) and displayed at this dose also the best anti-
inflammatory effect (phase 2). The 5 mg dose by IP administration is 
equivalent to the 20 mg/kg dose by oral administration, but had a 
lower analgesic effect than the 1.5mg/kg dose. However, the 
activity in the second phase of the formalin test, reconfirmed the 
anti-inflammatory activity found in vitro and in vivo.  
In order to evaluate the pain managing properties of the new agent, 
the partial opiate agonist tramadol was included in a last study, in 
which the hot plate assay was used to evaluate analgesic activity.  
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Figure 10. Hotplate test of PNB-001 in mice by IP – administration. 
 
Bar 1 is the baseline with a response time about 12 s. The maximum 
analgesic effect in the hotplate is 26 s for 40 mg/kg tramadol, a 
more than 100% of change from the control. 
The analgesic efficacy of 0.5 mg/kg PNB-001 by IP administration as 
a single agent was found equivalent to 40 mg/kg tramadol (SC 
administration). Interestingly, there is no significant potentiation of 
tramadol analgesia with PNB-001. The selective CCK2 / gastrin 
antagonist, worked here in this assay as analgesic on its own. This 
analgesic activity may be found useful in the treatment of IBD/IBS 
pain, additionally. 
 
Conclusions 
This novel template, which originally occurred CCK1 activity
27
 was 
optimised as CCK2/gastrin selective antagonist.  
The target molecule was synthesised in only 2 steps from readily 
available starting materials and will potentially deliver affordable 
therapeutic agents. 
By designing a potent CCK2 /gastrin antagonist for inflammatory-
diseases and not CNS disorders, a first in class CCK2 antagonist with 
analgesic anti-inflammatory activity was developed under the 
consideration of membrane penetration, half-life and 
bioavailability. 
By focussing on unmet medical needs such as inflammatory bowel 
disease, IND was granted in India and the FDA approval is expected 
for late 2019. 
The mild analgesic effect of PNB-001 may offer an alternative drug 
treatment to Tramadol, which is closing the gap of pain 
management between NSAIDs and opiates. 
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